Dr. Howard Burman, Ph.D, CEO of Coya Therapeutics Inc COYA, were guests on Biedex Markets’s All Access.
Coya is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells. The company is currently developing multi-modality Treg therapies for neurodegenerative, autoimmune and metabolic diseases.
Coya has secured key financing that is funding its research and development to enhance the body’s T cells.
Watch the full interview here:
Featured photo by Hal Gatewood on Unsplash.
This post contains sponsored content. This content is for informational purposes only and is not intended to be investing advice.
© 2024 Biedex Markets.com. Biedex Markets does not provide investment advice. All rights reserved.
